Our study aimed to examine whether molecular determinants such as the EGFR gene status and the EGFR downstream cascade members K-Ras and PTEN, which are altered in a significant proportion of sporadic CRC independently of the EGFR status, may serve as markers in predicting response in patients with mCRC treated with cetuximab. The gene discussed is PTEN; the disease is colorectal carcinoma.